Employees
77
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
better therapeutics (f/k/a farewell) is developing prescription digital therapeutics for treating chronic disease. its innovative solution combines software, human coaching augmented by artificial intelligence, and advanced analytics to address the behaviors at the root cause of most chronic conditions, in a manner that can scale rapidly to address millions of covered lives. better’s digital therapeutics are based on well-established evidence, fit within existing clinical treatment guidelines, and can be used with or without other interventions. better believes non-drug treatment options are essential to reducing the unnecessary health and cost burden of chronic disease on individuals, payers, and the nation.
Loading...
Open
0.00
Mkt cap
5.5K
Volume
3K
High
0.00
P/E Ratio
N/A
52-wk high
0.27
Low
0.00
Div yield
N/A
52-wk low
0.00
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 2:05 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 2:00 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 1:38 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 1:28 pm
Portfolio Pulse from Benzinga Newsdesk
March 05, 2024 | 2:30 pm
Portfolio Pulse from Benzinga Newsdesk
March 04, 2024 | 2:27 pm
Portfolio Pulse from Avi Kapoor
February 20, 2024 | 6:21 pm
Portfolio Pulse from Benzinga Insights
February 20, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
February 20, 2024 | 2:25 pm
Portfolio Pulse from Benzinga Insights
February 12, 2024 | 9:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.